Article

Eli Lilly and Nvidia are launching a $1 billion AI co-innovation lab in the San Francisco Bay Area to enhance drug discovery and development over the next five years. The facility will combine Lilly's pharmaceutical expertise with Nvidia's AI capabilities, utilizing the Nvidia BioNeMo platform to create a continuous learning system for efficient experimentation. Operations are set to begin in early 2026, building on prior collaborations aimed at accelerating drug development timelines.